Insmed lung drug sales surpass expectations in Q1 2025, while J&J secures a US pricing deal.
Browsing: Market & Financials
Market trends, financial performance, quarterly results, and investment insights from global pharma and biotech companies.
Biopharma CEO optimism varies globally, with US executives showing less confidence. Survey reveals differences in outlook.
Drug price deals with Trump involve 9 drugmakers, impacting tariffs and benefits. Analysts see limited financial effect.
Aktis IPO Filing comes as the biotech sector shows signs of recovery, raising hopes for a rebound in IPO activity in 2025.
Moderna H5 influenza vaccine receives undisclosed funding, reviving efforts after losing government support earlier this year.
Insmed drug failure in a study leads to a valuation drop of nearly 20%, affecting its $40 billion market cap.
Orum $100M financing supports its strategic shift towards developing a blood cancer treatment, enhancing its innovative pipeline.
RA Capital co-leads a $125 million Series A for Ambros Therapeutics, advancing a chronic pain drug nearing pivotal testing.
Addition Therapeutics secures $100M to advance RNA-lipid nanoparticle gene therapies, backed by Gates Foundation.
Apple Tree Ventures files for bankruptcy amid a funding dispute with billionaire backer, affecting its startups and restructuring plans.